title: [Preliminary study of new imaging agent, 99mTc-Rituximab, for sentinel lymph node biopsy of primary breast cancer].
abstract: OBJECTIVE
  To study the feasibility and effects of new imaging agent, 99mTc-Rituximab, for sentinel lymph nodes biopsy (SLNB) of primary breast cancer.
  
  
  METHODS
  SLNB were performed in eighty-five primary breast cancer patients using 99mTc-Rituximab combined with patent blue. Metastases in sentinel lymph nodes were detected with routine pathologic and immunohistochemistry method.
  
  
  RESULTS
  The successful rate of SLNB using combining method of 99mTc-Rituximab and patent blue was 96% (82/85). Thirty cases of SLN (37%, 30/82) were metastasis positive, including twenty-four positive cases by HE staining and six by immunohistochemistry method. SLN was the only metastasis lymph nodes in 18/30 cases. One case has false negative SLN metastasis. The sensitivity and accuracy of SLNB were 97% (30/31) and 99% (81/82). The specificity was 100% (51/51). The false negative rate was 3% (1/30) and the negative predictive value was 98% (51/52). The positive predictive value was 100% (31/31). Internal mammary sentinel lymph node lymphoscintigraphy was positive in eleven cases but all of them were confirmed metastases negative by pathologic examination.
  
  
  CONCLUSIONS
  99mTc-Rituximab, as a new imaging agent, can keep SLN imaging durable and can make SLNB more convenient. Through primary clinical manifestation, higher sensitivity and accuracy could obtained by combining method of 99mTc-Rituximab and patent blue for SLNB of primary breast cancer.
authors.affiliation: Breast Cancer Center, Beijing Cancer Hospital, the School of Oncology, Peking University, Beijing 100036, China.
authors.forename: Jin-feng
authors.initials: JF
authors.lastname: Li
authors.forename: Tao
authors.initials: T
authors.lastname: Ouyang
authors.forename: Xue-juan
authors.initials: XJ
authors.lastname: Wang
authors.forename: Tian-feng
authors.initials: TF
authors.lastname: Wang
authors.forename: Yun-tao
authors.initials: YT
authors.lastname: Xie
authors.forename: Zhao-qing
authors.initials: ZQ
authors.lastname: Fan
authors.forename: Bao-he
authors.initials: BH
authors.lastname: Lin
authors.forename: Zhi
authors.initials: Z
authors.lastname: Yang
authors.forename: Ben-yao
authors.initials: BY
authors.lastname: Lin
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001943:Breast Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D000069283:Rituximab; D012680:Sensitivity and Specificity; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*; D013667:Technetium
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D013667:Technetium